Trial Profile
A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin (Primary)
- Indications Agammaglobulinaemia; Bacterial infections; Immunodeficiency disorders
- Focus Registrational; Therapeutic Use
- Sponsors Grifols
- 13 Jun 2019 This trial has been completed in the Hungary, according to European clinical trial database
- 11 Jun 2019 This trial has been completed in the Czech Republic, according to European clinical trial database.
- 07 Jun 2019 This trial has been completed in the France, according to European clinical trial database.